• gmp-verlag.de
  • GMP Compliance Adviser Login
  • Shopping cart
Stay informed!

You’d like to be regularly informed on the latest developments in Good Manufacturing Practices?

 

Subscribe to our free GMP Newsletter LOGFILE!

>>> REGISTER NOW

2017 - The GMP Regulations Report

Have you considered all last years new regulations?

Make sure you did not miss out on one or the other with our overview of 24 important GMP documents published in 2017.


>>> Read now:
2017-Regulations-Report.pdf

GMP Compliance Adviser

GMP in Practice: 24 chapters written by internationally renowned industry experts.

 

GMP Regulations: 8 chapters with the most important GMP guidelines and regulations.

 

Image

>>> READ MORE

Award for the
GMP Compliance Adviser

GMP knowledge that convinces.

Image

On 7 June 2016 Maas & Peither GMP Publishing has received a

SIPAward in the category
"Best New Success Story" and was awarded with the 3rd place.

The GMP MANUAL (now: GMP Compliance Adviser) impressed the jury with "Safe Drugs through Better GMP Understanding".


TOP 5 GMP Downloads

1. Questionnaire for preparing GMP-inspections
More than 650 typical questions related to audits and inspections.


2. GMP Fundamentals
A quick and comprehensive overview of the complex world of GMP.


3. GDP Audit Questionnaire
More than 700 questions with reference to regulations.


4. A Pharma Guide to Cleaning Validation
How to meet Agency Expectations and Establish Accepted Limits.


5. Data Integrity in the EU
Requirements for Quality Management Systems.


>>> More Downloads

News about GMP/cGMP

2018-08-31

Six Asian Drug Manufacturers refuse FDA Inspection

The US Food and Drug Administration, FDA, has added six Asian drug manufacturers to its import alert list this month, that refused a planned inspection of the FDA.

 

The newly listed Asian manufacturers are from China (4), India (1) and South Korea (1):

  • Chifeng Wanze Pharmaceutical Co., China
  • Guangdong Jiaying Pharmaceutical, Ltd., China
  • Shenyang Funing Pharmaceutical Co., China
  • Guangdong Guangliang Industry Co., China
  • Gpt Pharmaceuticals Private, India
  • Dongkook Pharmaceutical Co., South Korea

The so called “Red List” identifies firms that have offered FDA-regulated articles for import into the United States and yet refused to allow the completion of an FDA inspection of their foreign establishment for the purpose of determining its conditions and compliance with applicable laws and regulations. Refusing to permit entry or inspection through FDA’s personnel always leads to the impression that something is wrong. It is furthermore strongly suspected that the products manufactured, processed or packaged are adulterated.

The reasons why these pharmaceutical manufacturers refused the inspections is still unknown.
Source:
Comments
No comment has yet been written about this news.
 
 
Literature recommendation
Questionnaire for preparing GMP-inspections
GDP Audit Questionnaire
GMP Compliance Adviser
Single User Licence (monthly subscription)